|
AstraZeneca PLC on Wednesday said its subsidiary Alexion Pharmaceuticals Inc, which focuses on rare diseases, will publish ‘new data showing significant advances’ regarding the treatment for a form of neuromyelitis with its drug Ultomiris.
The specific disease targeted is anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, or NMOSD, a rare condition with which the immune system damages the spinal cord and the optic nerves.
The Cambridge, England-based pharmaceutical company said that during a 73-week treatment period, no NMOSD patients on Ultomiris showed a worsening of their condition, known as relapse. This represents a near 99% reduction risk compared to a placebo. Safety and tolerability data were consistent with previous clinical studies. All tested patients were adults.
AstraZeneca will publish its data between October 26 and 28 at the European Committee for Treatment & Research in Multiple Sclerosis Congress.
AstraZeneca shares were 2.2% higher at 10,038.00 pence each in London on Wednesday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
